Gunter von Minckwitz MD, PhD

Gunter von Minckwitz is the Managing Director of the German Breast Group (GBG) Research Institute. GBG is the largest cooperative group in Germany working in the field of breast cancer with approximately 530 centres, 1100 collaborators and a recruitment of >32000 breast cancer patients into prospective clinical trials. He is also Alternate Director at Senologic Oncology, Breast Centre, Düsseldorf and a Professor and Consultant at the University Women’s of Frankfurt, Germany.

Professor von Minckwitz received his medical education at the University of Heidelberg and completed his fellowship and residency at the Women’s Hospital, University of Heidelberg, and the Women’s Hospital, University of Frankfurt, Germany. His areas of research include systemic treatment in all stages of the disease (neo-adjuvant, adjuvant, metastatic treatment and chemoprevention), where he has participated and led a large number of national and international clinical trials. He has improved the infrastructure for breast cancer trials all over Germany, and has founded and led the development of the national treatment guideline for breast cancer of the AGO from 2001 until 2006.

Professor von Minckwitz has authored and co-authored >200 medline listed scientific papers including, JCO, JNCI, Lancet, and NEJM, in addition to 450 review articles, book chapters and printed abstracts, as well as 16 books. He is on the board of directors of the Breast International Group (BIG), and has become member of the St. Gallen consensus panel in 2008 and the Early Breast Cancer trialists’ collaborative group (EBCTCG) in 2010. He received the Wertheim Award in 2009 and the Claudia-Schilling Award in 2012.